Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

Tomasz (Tom) Beer, W. C. Pierce, B. A. Lowe, W. D. Henner

    Research output: Contribution to journalArticle

    174 Citations (Scopus)

    Abstract

    Background: This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain. Patients and methods: Twenty-five patients were treated with docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment. This eight-week treatment cycle was repeated until progression or unacceptable toxicity. Endpoints included palliative response (a 2-point reduction on the 6-point Present Pain Intensity scale without an increase in analgesic consumption or a 50% decrease in analgesic use without an increase in pain), PSA response (a 50% decrease maintained at least four weeks), measurable disease response, survival, and toxicity. Results: Twelve of 25 patients (48%, 95% confidence interval (95% CI): 28%-68%) had a palliative response. Eleven of the 24 patients who entered with an elevated PSA (46%, 95% CI: 25%-67%) had a PSA response. Two of five patients with measurable disease had a partial response. Toxicity of therapy was modest with no treatment-related mortality. Twenty-five percent of patients experienced a grade 3 or 4 hematologic toxicity and 36% of patients experienced a grade 3 non-hematologic toxicity. Conclusions: Weekly docetaxel is well tolerated in patients with androgen-independent prostate cancer and has significant activity as measured by relief of pain, reduction in PSA, and reduction in measurable disease.

    Original languageEnglish (US)
    Pages (from-to)1273-1279
    Number of pages7
    JournalAnnals of Oncology
    Volume12
    Issue number9
    DOIs
    StatePublished - 2001

    Fingerprint

    docetaxel
    Androgens
    Prostatic Neoplasms
    Pain
    Analgesics
    Confidence Intervals
    Therapeutics

    Keywords

    • Adenocarcinoma of the prostate
    • Chemotherapy
    • Docetaxel
    • Prostate cancer

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. / Beer, Tomasz (Tom); Pierce, W. C.; Lowe, B. A.; Henner, W. D.

    In: Annals of Oncology, Vol. 12, No. 9, 2001, p. 1273-1279.

    Research output: Contribution to journalArticle

    Beer, Tomasz (Tom) ; Pierce, W. C. ; Lowe, B. A. ; Henner, W. D. / Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. In: Annals of Oncology. 2001 ; Vol. 12, No. 9. pp. 1273-1279.
    @article{2cd1723d513e4c868daf17d4eb24f4dd,
    title = "Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer",
    abstract = "Background: This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain. Patients and methods: Twenty-five patients were treated with docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment. This eight-week treatment cycle was repeated until progression or unacceptable toxicity. Endpoints included palliative response (a 2-point reduction on the 6-point Present Pain Intensity scale without an increase in analgesic consumption or a 50{\%} decrease in analgesic use without an increase in pain), PSA response (a 50{\%} decrease maintained at least four weeks), measurable disease response, survival, and toxicity. Results: Twelve of 25 patients (48{\%}, 95{\%} confidence interval (95{\%} CI): 28{\%}-68{\%}) had a palliative response. Eleven of the 24 patients who entered with an elevated PSA (46{\%}, 95{\%} CI: 25{\%}-67{\%}) had a PSA response. Two of five patients with measurable disease had a partial response. Toxicity of therapy was modest with no treatment-related mortality. Twenty-five percent of patients experienced a grade 3 or 4 hematologic toxicity and 36{\%} of patients experienced a grade 3 non-hematologic toxicity. Conclusions: Weekly docetaxel is well tolerated in patients with androgen-independent prostate cancer and has significant activity as measured by relief of pain, reduction in PSA, and reduction in measurable disease.",
    keywords = "Adenocarcinoma of the prostate, Chemotherapy, Docetaxel, Prostate cancer",
    author = "Beer, {Tomasz (Tom)} and Pierce, {W. C.} and Lowe, {B. A.} and Henner, {W. D.}",
    year = "2001",
    doi = "10.1023/A:1012258723075",
    language = "English (US)",
    volume = "12",
    pages = "1273--1279",
    journal = "Annals of Oncology",
    issn = "0923-7534",
    publisher = "Oxford University Press",
    number = "9",

    }

    TY - JOUR

    T1 - Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

    AU - Beer, Tomasz (Tom)

    AU - Pierce, W. C.

    AU - Lowe, B. A.

    AU - Henner, W. D.

    PY - 2001

    Y1 - 2001

    N2 - Background: This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain. Patients and methods: Twenty-five patients were treated with docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment. This eight-week treatment cycle was repeated until progression or unacceptable toxicity. Endpoints included palliative response (a 2-point reduction on the 6-point Present Pain Intensity scale without an increase in analgesic consumption or a 50% decrease in analgesic use without an increase in pain), PSA response (a 50% decrease maintained at least four weeks), measurable disease response, survival, and toxicity. Results: Twelve of 25 patients (48%, 95% confidence interval (95% CI): 28%-68%) had a palliative response. Eleven of the 24 patients who entered with an elevated PSA (46%, 95% CI: 25%-67%) had a PSA response. Two of five patients with measurable disease had a partial response. Toxicity of therapy was modest with no treatment-related mortality. Twenty-five percent of patients experienced a grade 3 or 4 hematologic toxicity and 36% of patients experienced a grade 3 non-hematologic toxicity. Conclusions: Weekly docetaxel is well tolerated in patients with androgen-independent prostate cancer and has significant activity as measured by relief of pain, reduction in PSA, and reduction in measurable disease.

    AB - Background: This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain. Patients and methods: Twenty-five patients were treated with docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment. This eight-week treatment cycle was repeated until progression or unacceptable toxicity. Endpoints included palliative response (a 2-point reduction on the 6-point Present Pain Intensity scale without an increase in analgesic consumption or a 50% decrease in analgesic use without an increase in pain), PSA response (a 50% decrease maintained at least four weeks), measurable disease response, survival, and toxicity. Results: Twelve of 25 patients (48%, 95% confidence interval (95% CI): 28%-68%) had a palliative response. Eleven of the 24 patients who entered with an elevated PSA (46%, 95% CI: 25%-67%) had a PSA response. Two of five patients with measurable disease had a partial response. Toxicity of therapy was modest with no treatment-related mortality. Twenty-five percent of patients experienced a grade 3 or 4 hematologic toxicity and 36% of patients experienced a grade 3 non-hematologic toxicity. Conclusions: Weekly docetaxel is well tolerated in patients with androgen-independent prostate cancer and has significant activity as measured by relief of pain, reduction in PSA, and reduction in measurable disease.

    KW - Adenocarcinoma of the prostate

    KW - Chemotherapy

    KW - Docetaxel

    KW - Prostate cancer

    UR - http://www.scopus.com/inward/record.url?scp=0034772296&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0034772296&partnerID=8YFLogxK

    U2 - 10.1023/A:1012258723075

    DO - 10.1023/A:1012258723075

    M3 - Article

    C2 - 11697840

    AN - SCOPUS:0034772296

    VL - 12

    SP - 1273

    EP - 1279

    JO - Annals of Oncology

    JF - Annals of Oncology

    SN - 0923-7534

    IS - 9

    ER -